.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
McKinsey
Federal Trade Commission
Covington
Cipla
Julphar
Harvard Business School
UBS
Fish and Richardson
Healthtrust

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,834,059

« Back to Dashboard

Which drugs does patent 7,834,059 protect, and when does it expire?


Patent 7,834,059 protects NEVANAC and is included in one NDA.

This patent has twenty-three patent family members in twenty-two countries.

Summary for Patent: 7,834,059

Title:Topical nepafenac formulations
Abstract:Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
Inventor(s): Wong; Warren (Fort Worth, TX)
Assignee: Alcon, Inc. (Hunenberg, CH)
Application Number:11/292,484
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms CorpNEVANACnepafenacSUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF TREATING OCULAR INFLAMMATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,834,059

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,071,648Topical nepafenac formulations► Subscribe
8,324,281Topical nepafenac formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,834,059

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2586807► Subscribe
China101068573► Subscribe
Cyprus1110780► Subscribe
Germany602005022756► Subscribe
Denmark1819362► Subscribe
Japan4968844► Subscribe
European Patent Office1819362► Subscribe
Spain2348249► Subscribe
Hong Kong1104225► Subscribe
Japan2008521926► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Farmers Insurance
Dow
Harvard Business School
Fuji
Baxter
Chubb
Covington
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot